Franchise Global Health is a multi-national operator in the medical cannabis and pharmaceutical industries with operations, assets, strategic partnerships and investments in Germany, Canada, St. Vincent & the Grenadines, Portugal and Denmark. Franchise is committed to develop a fully integrated, leading European medical cannabis business with the goal of providing high-quality pharmaceutical grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices.
In Germany, Franchise Global Health has its principal operations headquartered in Konstanz, Germany. Through its German subsidiaries, Franchise is an importer, exporter and distributor of prescription drugs and EU-GMP medical cannabis. EU-GMP certifications are issued and regulated by BfArM.
ACA Müller, Franchise’s wholly-owned German subsidiary, obtained the first medical cannabis import and distribution license in Germany in March 2017 and since then, has sold medical cannabis to over 1,200 pharmacies across Germany. Company facilities include vault systems for cannabis and narcotics storage, logistics and distribution facilities run by expert employees.
Phatebo is a wholesale pharmaceutical distribution company with import and export capabilities for a wide range of pharmaceutical and medical cannabis products. They hold licenses for the Trade in Narcotic Drugs and wholesale trade, both of which are issued by BfArM. In 2018, Phatebo received a medical cannabis import and distribution license and has established sales to German pharmacies. They have developed distribution networks within 18 countries globally including Europe, Asia, Latin America, and North America.
Franchise is perfectly positioned to service the German domestic medical Cannabis market and other international markets.
In Canada, Franchise Global Health has obtained access to 500,000 square feet of reserved cultivation capacity at an EU-GMP certified facility through a strategic partnership with a licensed producer in Ontario, Canada. And a further 30,000 square foot EU-GMP processing facility on site. Production will be exported to the Company’s German subsidiaries for onward distribution and sale in Europe and other global markets.
In St. Vincent, Franchise has entered into a strategic partnership with Satica Medical Ltd and the Company intends to work with this cultivator to achieve import of low-cost, high-quality, tropical-grown cannabis internationally.
In Portugal, Franchise has strategic supply agreements in place and has entered into a strategic investment with a licensed cultivator.
In Denmark, the Company’s Danish subsidiary has a license to store, sell and export cannabis genetics.